MedDataX Logo

Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects

NCT ID: NCT03001271

Last Updated: 2016-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the modern concept of Renin-angiotensin System, Angiotensin-(1-7) plays a key role and demonstrates promising therapeutic potential due to it is generally opposite effects to Angiotensin II. The aim is to evaluate the effect of Ang-(1-7) acute administration on systolic and diastolic blood pressure (SBP and DBP) and heart rate (HR) in healthy and hypertensive subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Angiotensin-(1-7) Renin-angiotensin System Autonomic Nervous System

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Subjects

Placebo and Angiotensin-(1-7) acute infusion

Group Type EXPERIMENTAL

Angiotensin 1-7

Intervention Type DRUG

Placebo

Intervention Type OTHER

Hypertensive Subjects

Placebo and Angiotensin-(1-7) acute infusion

Group Type EXPERIMENTAL

Angiotensin 1-7

Intervention Type DRUG

Placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Angiotensin 1-7

Intervention Type DRUG

Placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Angio-1-7

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* arterial pressure \<140/90 mmHg
* body mass index (BMI) between 18,5 and 29 Kg/m2


* anti-hypertensive drug treatment
* ambulatory blood pressure monitoring (ABMP) \>130/85 mmHg
* body mass index between 18,5 and 29 Kg/m2

Exclusion Criteria

* drug treatment
* recent surgeries
* pregnancy
* previous cardiovascular events
* high performance athletes
* dislipidemia
* diabetes
* renal injury
* obesity (BMI above 30 kg/m2)
* alcoholism
* smoking.


* recent surgeries
* pregnancy
* beta-blockers drug treatment
* previous cardiovascular events
* high performance athletes
* dislipidemia
* diabetes
* renal injury
* obesity (BMI above 30 kg/m2)
* alcoholism
* smoking
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto de Cardiologia do Rio Grande do Sul

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4576/10

Identifier Type: -

Identifier Source: org_study_id